AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in

the application:

Listing of Claims

Claims 1-52. (Canceled).

Claim 53. (Currently Amended): A method for inhibiting renal uptake of

proteins and peptides used for therapeutic or diagnostic purposes that possibly may be

damaging to the kidneys of a subject, consisting essentially of:

administering a combination of two amino acids: a first amino acid which is a

lysine selected from the group consisting of D-lysine, L-lysine and poly-lysine, or a

pharmaceutically acceptable salt or carboxylic acid derivative thereof; and a second amino

acid which is selected from the group consisting of arginine and ornithine, or a

pharmaceutically acceptable salt or carboxylic acid derivative thereof,

wherein the first amino acid is administered in an amount of about 15-35 20-

30 grams per treatment and the second amino acid is administered in an amount of about 15-

35 20-30 grams per treatment.

Claim 54-55. (Canceled)

Claim 56. (Previously Presented): The method of claim 53, wherein the first

amino acid is provided in an amount of about 25 grams and the second amino acid is

provided in an amount of about 25 grams per treatment.

2

Claim 57. (Previously Presented): The method of claim 53, wherein the

second amino acid is arginine.

Claim 58. (Currently Amended): A therapeutic composition for inhibiting

renal uptake of protein or peptides used for therapeutic or diagnostic purposes that possibly

may be damaging to the kidneys of a subject, consisting essentially of:

one or more pharmaceutically acceptable excipients, carriers or diluents and a

combination of:

a first amino acid which is a lysine selected from the group consisting of D-

lysine, L-lysine and poly-lysine, or a pharmaceutically acceptable salt or carboxylic acid

derivative thereof; and

a second amino acid which is selected from the group consisting of arginine

and ornithine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof,

wherein the first amino acid is provided in an amount of about 15-35 20-30

grams per treatment, and the second amino acid is provided in an amount of about 15-35 20-

30 grams per treatment.

Claim 59-60. (Canceled)

Claim 61 (Previously Presented): The therapeutic composition of claim 58,

wherein the first amino acid is provided in an amount of about 25 grams and the second

amino acid is provided in an amount of about 25 grams per treatment.

3

Claim 62 (Previously Presented): The therapeutic composition of claim 58,

wherein the second amino acid is arginine.

Claim 63 (Previously Presented): The therapeutic composition of claim 58,

wherein the first amino acid and the second amino acid or their respective derivatives thereof

are present in about 1 L infusion fluid.

Claim 64. (Canceled)

Claim 65. (New): The method of claim 53, wherein the osmolarity of the

combination of two amino acids is about 400 mosmol/L.

Claim 66. (New): The therapeutic composition of claim 58, wherein the

osmolarity of the composition is about 400 mosmol/L.

4